drugset / Trial / NCT00026377
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, bicalutamide, leuprolide, or goserelin may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining SU5416, hormone therapy, and radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of SU5416 plus hormone therapy and radiation therapy in treating patients who have prostate cancer.
Timeline
- Start
- 2001-11
- Primary completion
- 2002-03
- Completion
- 2003-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | semaxanib | Small molecule | — | Intravenous |
| Background | Bicalutamide | Other / unclassified | 50 mg | Oral |
| Background | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Background | Leuprolide | Other / unclassified | 7.5 mg | Subcutaneous |
| Background | flutamide | Small molecule | 250 mg | Oral |